{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:58:27Z","timestamp":1789095507281,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10403-8","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T01:11:02Z","timestamp":1741137062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies"],"prefix":"10.1007","volume":"52","author":[{"given":"Emirhan","family":"Harbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"10403_CR1","doi-asserted-by":"crossref","unstructured":"Kaelin (2002) Molecular basis of the VHL hereditary cancer syndrome. Cancer pp. 673\u2013682","DOI":"10.1038\/nrc885"},{"key":"10403_CR2","doi-asserted-by":"crossref","unstructured":"Chittiboina P, Lonser RR (2015) Von Hippel-Lindau disease. Handbook of clinical neurology. pp. 139\u2013156","DOI":"10.1016\/B978-0-444-62702-5.00010-X"},{"key":"10403_CR3","volume-title":"Von Hippel-Lindau syndrome","author":"AS Leeuwaarde","year":"2024","unstructured":"Leeuwaarde AS, van Nesselrooij B (2024) Von Hippel-Lindau syndrome. GeneReviews, s.l."},{"key":"10403_CR4","doi-asserted-by":"crossref","unstructured":"Devarajan P, De Leon M, Talasazan F, Schoenfeld AR, Davidowitz EJ, Burk RD (2001) The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J Biol Chem pp. 40599\u201340605","DOI":"10.1074\/jbc.M103424200"},{"key":"10403_CR5","doi-asserted-by":"crossref","unstructured":"Ohh M, Taber CC, Ferens FG, Tarade D (2022) Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata. eLife p. e80774","DOI":"10.7554\/eLife.80774"},{"key":"10403_CR6","doi-asserted-by":"crossref","unstructured":"Choueiri. TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S (2013) The role of aberrant VHL\/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin cancer Research: Official J Am Association Cancer Res pp. 5218\u20135226","DOI":"10.1158\/1078-0432.CCR-13-0491"},{"key":"10403_CR7","doi-asserted-by":"crossref","unstructured":"Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N, Zhang D, Liu Q, Jiang J (2020) The VHL\/HIF Axis in the development and treatment of pheochromocytoma\/paraganglioma. Front Endocrinol","DOI":"10.3389\/fendo.2020.586857"},{"key":"10403_CR8","doi-asserted-by":"crossref","unstructured":"Schmid S, Gillessen S, Binet I, Br\u00e4ndle M, Engeler D, Greiner J, Hader C, Heinimann K, Kloos P, Krek W, Krull I, Stoeckli SJ, Sulz MC, van Leyen K, Weber J, Rothermundt C, Hundsberger T (2014) Management of von hippel-lindau disease: an interdisciplinary review. Oncol Res Treat pp. 761\u2013771","DOI":"10.1159\/000369362"},{"key":"10403_CR9","doi-asserted-by":"crossref","unstructured":"Kim (2018) Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Frontiers in pediatrics.","DOI":"10.3389\/fped.2018.00016"},{"key":"10403_CR10","volume-title":"Von Hippel-Lindau syndrome","author":"S van Leeuwaarde, Ahmad","year":"2000","unstructured":"van Leeuwaarde, Ahmad S, van Nesselrooij B et al (2000) Von Hippel-Lindau syndrome. GeneReviews\u00ae [Internet], s.l."},{"key":"10403_CR11","doi-asserted-by":"crossref","unstructured":"del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri MO (2003) The von Hippel Lindau\/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem pp. 48690\u201348695","DOI":"10.1074\/jbc.M308862200"},{"key":"10403_CR12","doi-asserted-by":"crossref","unstructured":"Haase., Haase V (2009) The VHL tumor suppressor: master regulator of HIF. Current pharmaceutical design. pp. 3895\u20133903","DOI":"10.2174\/138161209789649394"},{"key":"10403_CR13","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang Q (2018) VHL and hypoxia signaling: beyond HIF in Cancer. Biomedicines","DOI":"10.3390\/biomedicines6010035"},{"key":"10403_CR14","doi-asserted-by":"crossref","unstructured":"Ohh. M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell pp. 959\u2013968","DOI":"10.1016\/S1097-2765(00)80096-9"},{"key":"10403_CR15","doi-asserted-by":"crossref","unstructured":"Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M (2004) pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol pp. 3251\u20133261","DOI":"10.1128\/MCB.24.8.3251-3261.2004"},{"key":"10403_CR16","doi-asserted-by":"crossref","unstructured":"Roe JS, Youn HD The positive regulation of p53 by the tumor suppressor VHL. Cell cycle (Georgetown, Tex.). 2006, pp. 2054\u20132056","DOI":"10.4161\/cc.5.18.3247"},{"key":"10403_CR17","doi-asserted-by":"crossref","unstructured":"Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol pp. 64\u201370","DOI":"10.1038\/ncb899"},{"key":"10403_CR18","doi-asserted-by":"crossref","unstructured":"Klingler JH, Gl\u00e4sker S, Bausch B, Urbach H, Krauss T, Jilg CA, Steiert C, Puzik A, Neumann-Haefelin E, Kotsis F, Agostini H, Neumann HPH, Beck J (2020) Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Child\u2019s Nerv Syst pp. 2537\u20132552","DOI":"10.1007\/s00381-020-04712-5"},{"key":"10403_CR19","unstructured":"Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, Giraud S, B\u00e9roud C, Dureau P, Gaudric A, Landais P, Richard S (2002) Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Investig Ophthalmol Vis Sci pp. 3067\u20133074"},{"key":"10403_CR20","doi-asserted-by":"crossref","unstructured":"Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, Aronow ME, Chew E (2019) Y. MANAGEMENT OF RETINAL HEMANGIOBLASTOMA IN VON HIPPEL-LINDAU DISEASE. Retina (Philadelphia, Pa.). pp. 2254\u20132263","DOI":"10.1097\/IAE.0000000000002572"},{"key":"10403_CR21","doi-asserted-by":"crossref","unstructured":"Castro-Teles J, Sousa-Pinto B, Rebelo S, Pignatelli D (2021) Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack. Endocr Connections pp. R293\u2013R304","DOI":"10.1530\/EC-21-0294"},{"key":"10403_CR22","doi-asserted-by":"crossref","unstructured":"Frederik JWM, H\u00f6ppener, Cornelis JM (2003) Lips. Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metabolism pp. 969\u2013974","DOI":"10.1210\/jc.2002-021466"},{"key":"10403_CR23","doi-asserted-by":"crossref","unstructured":"Kantorovich V, Pacak K (2010) Pheochromocytoma and paraganglioma. Prog Brain Res pp. 343\u2013373","DOI":"10.1016\/S0079-6123(10)82015-1"},{"key":"10403_CR24","doi-asserted-by":"crossref","unstructured":"Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S (2019) Treatment options for pancreatic neuroendocrine tumors. Cancers","DOI":"10.3390\/cancers11060828"},{"key":"10403_CR25","doi-asserted-by":"crossref","unstructured":"Hackert T, B\u00fcchler MW, Werner J (2011) Current state of surgical management of pancreatic cancer. Cancers pp. 1253\u20131273","DOI":"10.3390\/cancers3011253"},{"key":"10403_CR26","doi-asserted-by":"crossref","unstructured":"Kim (2005) Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg pp. 503\u2013512","DOI":"10.3171\/jns.2005.102.3.0503"},{"key":"10403_CR27","doi-asserted-by":"crossref","unstructured":"Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K, Zbar B, Linehan WM, Walther MM (1997) Epididymal cystadenomas in von Hippel-Lindau disease. Urology pp. 926\u2013931","DOI":"10.1016\/S0090-4295(97)00074-5"},{"key":"10403_CR28","doi-asserted-by":"crossref","unstructured":"Haase (2006) The VHL\/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int pp. 1302\u20131307","DOI":"10.1038\/sj.ki.5000221"},{"key":"10403_CR29","doi-asserted-by":"crossref","unstructured":"Na X, Wu G, Ryan CK, Schoen SR, di\u2019Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol pp. 588\u2013592","DOI":"10.1097\/01.ju.0000074870.54671.98"},{"key":"10403_CR30","doi-asserted-by":"crossref","unstructured":"Kapitsinou PP, Haase VH (2008) The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ pp. 650\u2013659","DOI":"10.1038\/sj.cdd.4402313"},{"key":"10403_CR31","doi-asserted-by":"crossref","unstructured":"Kim., Zschiedrich S (2018) Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Frontiers in pediatrics.","DOI":"10.3389\/fped.2018.00016"},{"key":"10403_CR32","doi-asserted-by":"crossref","unstructured":"Pastore AL, Palleschi G, Silvestri L, Moschese D, Ricci S, Petrozza V, Carbone A, Di Carlo A (2015) Serum and urine biomarkers for human renal cell carcinoma. Dis Markers","DOI":"10.1155\/2015\/251403"},{"key":"10403_CR33","doi-asserted-by":"crossref","unstructured":"Zhu W, Zheng G, Yan X, Liu M, Li X, Cheng Y, Bai C, Zhang Y, Huo L (2024) Diagnostic efficacy of [68Ga]Ga-NY104 PET\/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging pp. 4127\u20134133","DOI":"10.1007\/s00259-024-06801-y"},{"key":"10403_CR34","doi-asserted-by":"crossref","unstructured":"Choueiri (2020) Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med pp. 1519\u20131530","DOI":"10.1038\/s41591-020-1093-z"},{"key":"10403_CR35","doi-asserted-by":"crossref","unstructured":"Friedrich (1999) Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer pp. 2478\u20132482","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5"},{"key":"10403_CR36","doi-asserted-by":"crossref","unstructured":"Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, Nathanson KL, States LJ, Tomlinson GE, Villani A, Voss SD, Schiffman JD, Wasserman JD (2017) Von Hippel-Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin cancer Research: Official J Am Association Cancer Res pp. e68\u2013e75","DOI":"10.1158\/1078-0432.CCR-17-0547"},{"key":"10403_CR37","doi-asserted-by":"crossref","unstructured":"Hudler P, Urbancic M (2022) The role of VHL in the development of von Hippel-Lindau disease and erythrocytosis. Genes","DOI":"10.3390\/genes13020362"},{"key":"10403_CR38","doi-asserted-by":"crossref","unstructured":"Casey RT, Warren AY, Martin JE, Challis BG, Rattenberry E, Whitworth J, Andrews KA, Roberts T, Clark GR, West H, Smith PS, Docquier FM, Rodger F, Murray V, Simpson HL, Wallis Y, Giger O, Tran M (2017) Tomkin. Clinical and Molecular Features of Renal and Pheochromocytoma\/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. The Journal of clinical endocrinology and metabolism. pp. 4013\u20134022","DOI":"10.1210\/jc.2017-00562"},{"key":"10403_CR39","doi-asserted-by":"crossref","unstructured":"Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA pp. 1427\u20131434","DOI":"10.1001\/jama.287.11.1427"},{"key":"10403_CR40","doi-asserted-by":"crossref","unstructured":"Garg MK, Kharb S, Brar KS, Gundgurthi A, Mittal R (2011) Medical management of pheochromocytoma: role of the endocrinologist. Indian J Endocrinol Metabol pp. S329\u2013S336","DOI":"10.4103\/2230-8210.86976"},{"key":"10403_CR41","doi-asserted-by":"crossref","unstructured":"V\u00e1clav\u00edk J, Stejskal D, Lacn\u00e1k B, Laz\u00e1rov\u00e1 M, Jedelsk\u00fd L, Kadalov\u00e1 L, Janosov\u00e1 M, Frys\u00e1k Z, Vlcek P (2007) Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens pp. 1427\u20131431","DOI":"10.1097\/HJH.0b013e32813aeb5a"},{"key":"10403_CR42","doi-asserted-by":"crossref","unstructured":"B\u00edlek R, Vl\u010dek P, \u0160afa\u0159\u00edk L, Michalsk\u00fd D, Nov\u00e1k K, Du\u0161kov\u00e1 J, V\u00e1clav\u00edkov\u00e1 E, Widimsk\u00fd J, Jr, Zelinka T (2019) Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers.","DOI":"10.3390\/cancers11040586"},{"key":"10403_CR43","doi-asserted-by":"crossref","unstructured":"Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, Pacak K (2021) Imaging of pheochromocytoma and paraganglioma. J Nuclear Medicine: Official Publication Soc Nuclear Med pp. 1033\u20131042","DOI":"10.2967\/jnumed.120.259689"},{"key":"10403_CR44","doi-asserted-by":"crossref","unstructured":"Timmers HJLM, Ta\u00efeb D, Pacak K, Lenders J (2024) W. M. Imaging of pheochromocytomas and paragangliomas. Endocr Rev pp. 414\u2013434","DOI":"10.1210\/endrev\/bnae001"},{"key":"10403_CR45","doi-asserted-by":"crossref","unstructured":"Pacak K (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab pp. 4069\u20134079","DOI":"10.1210\/jc.2007-1720"},{"key":"10403_CR46","doi-asserted-by":"crossref","unstructured":"Ramachandran R, Rewari V (2017) Current perioperative management of pheochromocytomas. Indian J Urology: IJU: J Urol Soc India pp. 19\u201325","DOI":"10.4103\/0970-1591.194781"},{"key":"10403_CR47","doi-asserted-by":"crossref","unstructured":"\u00d6berg K (2018) Management of functional neuroendocrine tumors of the pancreas. Gland surgery. pp. 20\u201327","DOI":"10.21037\/gs.2017.10.08"},{"key":"10403_CR48","doi-asserted-by":"crossref","unstructured":"Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E (2018) Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease. JAMA Oncol. pp. 124\u2013126","DOI":"10.1001\/jamaoncol.2017.3428"},{"key":"10403_CR49","doi-asserted-by":"crossref","unstructured":"Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA (2020) & P. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. pp. 1\u201333","DOI":"10.1097\/MPA.0000000000001454"},{"key":"10403_CR50","doi-asserted-by":"crossref","unstructured":"Lee A, Chan DL, Wong MH, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N (2017) Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors. Neuroendocrinology pp. 209\u2013222","DOI":"10.1159\/000446115"},{"key":"10403_CR51","doi-asserted-by":"crossref","unstructured":"Hong B, Ma K, Zhou J, Zhang J, Wang J, Liu S, Zhang Z, Cai L, Zhang N, Gong K (2019) Frequent mutations of VHL gene and the clinical phenotypes in the largest Chinese cohort with von Hippel-Lindau disease. Front Genet","DOI":"10.3389\/fgene.2019.00867"},{"key":"10403_CR52","doi-asserted-by":"crossref","unstructured":"Zanoletti E, Girasoli L, Borsetto D, Opocher G, Mazzoni A, Martini A (2017) Endolymphatic sac tumour in von Hippel-Lindau disease: management strategies. Acta otorhinolaryngologica Italica: organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale. pp. 423\u2013429","DOI":"10.14639\/0392-100X-1402"},{"key":"10403_CR53","doi-asserted-by":"crossref","unstructured":"Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, Gl\u00e4sker S, Schmid KW, Wiech T, Preuss SF, Su\u00e1rez C, Kope\u0107 T, Patocs A, Wohllk N, Malekpour M, Boedeker CC, Neumann HP (2012) Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo, Brazil). pp. 19\u201328","DOI":"10.6061\/clinics\/2012(Sup01)05"},{"key":"10403_CR54","doi-asserted-by":"crossref","unstructured":"Kaelin (2022) Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Investig p. e162480","DOI":"10.1172\/JCI162480"},{"key":"10403_CR55","doi-asserted-by":"crossref","unstructured":"Else T, Wong KK, Frey KA, Brooks AF, Viglianti BL, Raffel DM (2024) 3-[18F]Fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) PET-A novel imaging modality for paraganglioma. J Endocr Soc","DOI":"10.1210\/jendso\/bvae049"},{"key":"10403_CR56","doi-asserted-by":"crossref","unstructured":"Fang F, Ding L, He Q, Liu M (2020) Preoperative Management of Pheochromocytoma and Paraganglioma. Frontiers in endocrinology.","DOI":"10.3389\/fendo.2020.586795"},{"key":"10403_CR57","doi-asserted-by":"crossref","unstructured":"Mehta GU, Shively SB, Gl\u00e4sker S, Bechert CJ, Zhuang Z, Raffeld M, Lonser RR, Oldfield EH, Vortmeyer AO (2007) Von Hippel-Lindau disease: epididymal cystadenoma targeted by metastatic events. Urology","DOI":"10.1016\/j.urology.2007.03.047"},{"key":"10403_CR58","doi-asserted-by":"crossref","unstructured":"Odrzywolski KJ, Mukhopadhyay S (2010) Papillary cystadenoma of the epididymis. Arch Pathol Lab Med pp. 630\u2013633","DOI":"10.5858\/134.4.630"},{"key":"10403_CR59","doi-asserted-by":"crossref","unstructured":"Papadakis GZ, Millo C, Sadowski SM, Bagci U, Patronas NJ (2016) Epididymal cystadenomas in von Hippel-Lindau disease showing increased activity on 68Ga DOTATATE PET\/CT. Clin Nucl Med pp. 781\u2013782","DOI":"10.1097\/RLU.0000000000001314"},{"key":"10403_CR60","doi-asserted-by":"crossref","unstructured":"Gl\u00e4sker S, Vergauwen E, Koch CA, Kutikov A, Vortmeyer AO (2020) Von Hippel-Lindau disease: current challenges and future prospects. OncoTargets Therapy pp. 5669\u20135690","DOI":"10.2147\/OTT.S190753"},{"key":"10403_CR61","doi-asserted-by":"crossref","unstructured":"Lehmann H, Vicari D, Wild PJ, Frew IJ (2015) Combined deletion of Vhl and Kif3a accelerates renal cyst formation. J Am Soc Nephrology: JASN pp. 2778\u20132788","DOI":"10.1681\/ASN.2014090875"},{"key":"10403_CR62","doi-asserted-by":"crossref","unstructured":"van Asselt SJ, de Vries EG, van Dullemen HM, Brouwers AH, Walenkamp AM, Giles RH, Links TP (2013) Pancreatic cyst development: insights from von Hippel-Lindau disease. Cilia","DOI":"10.1186\/2046-2530-2-3"},{"key":"10403_CR63","doi-asserted-by":"crossref","unstructured":"Ayloo S, Molinari M (2016) Pancreatic manifestations in von Hippel-Lindau disease: A case report. Int J Surg Case Rep pp. 70\u201372","DOI":"10.1016\/j.ijscr.2016.02.031"},{"key":"10403_CR64","doi-asserted-by":"crossref","unstructured":"Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A (2022) & Pancreatic manifestations recommendations development subcommittee of the VHL alliance. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer pp. 435\u2013446","DOI":"10.1002\/cncr.33978"},{"key":"10403_CR65","unstructured":"Slater A, Moore NR, Huson SM (2003) The natural history of cerebellar hemangioblastomas in von Hippel-Lindau disease. AJNR Am J Neuroradiol pp. 1570\u20131574"},{"key":"10403_CR66","doi-asserted-by":"crossref","unstructured":"Brauch H, Kishida T, Glavac D, Chen F, Pausch F, H\u00f6fler H, Latif F, Lerman MI, Zbar B, Neumann HP (1995) Von Hippel-Lindau (VHL) disease with pheochromocytoma in the black forest region of Germany: evidence for a founder effect. Hum Genet pp. 551\u2013556","DOI":"10.1007\/BF00223868"},{"key":"10403_CR67","doi-asserted-by":"crossref","unstructured":"Liu P, Zhu F, Li M, Dube DA, Liu Q, Wang C, Xiao Q, Zhang L, Gao S, Li Z, Zhang B, Liu J, Liu L, Chen X (2019) Von Hippel-Lindau black forest mutation inherited in a large Chinese family. Gland Surg pp. 343\u2013353","DOI":"10.21037\/gs.2019.08.03"},{"key":"10403_CR68","doi-asserted-by":"crossref","unstructured":"Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H.,Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., Dorff, S. E., Chambers,W. A., Mixter, B. D., Dinin, J., Pierce, W. F.,\u2026 Beaver, J. A. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.Clinical cancer research: an official journal of the American Association for Cancer Research. 2022, pp. 4843\u20134848.","DOI":"10.1158\/1078-0432.CCR-22-1054"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10403-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10403-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10403-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:37:46Z","timestamp":1766853466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10403-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10403"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10403-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not involve any human or animal participants, nor does it require ethical approval. Therefore, statements regarding ethical approval, consent to participate, or consent to publish are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}